CXCR4 and plasma cell myeloma: Seamlessly completing the theranostic loop, the therapeutic counterparts [<sup>177</sup>Lu]/[<sup>90</sup>Y]Pentixather deliver targeted radiotherapy to CXCR4-expressing tissues, with pioneering applications in advanced multiple myeloma and acute myeloid leukemia establishing a compelling safety and efficacy profile.